Amgen Reveals Post-Hoc Data For Its KRAS Inhibitor In Lung Cancer Patients

• Amgen Inc (NASDAQ: AMGN) announced results from two analyses of the Phase 2 CodeBreaK 100 trial evaluating Lumakras (sotorasib).

• Lumakras, a KRASG12C inhibitor, is approved in the U.S. for previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).

• Related Content: Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer.

• In a post-hoc analysis of 40 patients, Lumakras achieved a 77.5% disease control rate (DCR), similar to patients without brain metastases.

• A median progression-free survival (PFS) of 5.3 months and median overall survival (OS) of 8.3 months were observed.

• In patients evaluable by Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, 14 of 16 patients (88%) maintained intracranial disease control of their stable brain lesions during Lumakras therapy with two achieving complete responses of non-target lesions.

• The safety profile of Lumakras in the brain metastases group was consistent with previous reports.

• Amgen is enrolling patients with active brain metastases in an arm of the CodeBreaK 101 study.

• Price Action: AMGN stock is down 0.41% at $219.97 during the premarket session on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Amgen, AstraZeneca Tout Additional Data From Asthma Trial With Tezepelumab

• Amgen's Repatha Improves Plaque Stability In Heart Patients

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.